Influenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Influenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated)
Accession Number
DB10791
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Description
Not Available
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza a virus a/california/7/2009 x-179a (h1n1) hemagglutinin antigen (formaldehyde inactivated)hemagglutininC8E791RO82Not AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (9 ug/0.1mL) + Influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (formaldehyde inactivated) (9 ug/0.1mL) + Influenza b virus b/massachusetts/2/2012 antigen (formaldehyde inactivated) (9 ug/0.1mL)Injection, suspensionIntradermalSanofi Pasteur Limited2013-06-282014-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/massachusetts/2/2012 bx-51b antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2014-06-272015-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/victoria/210/2009 x-187 (h3n2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2010-07-232011-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/victoria/210/2009 x-187 (h3n2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2011-07-012012-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (9 ug/0.1mL) + Influenza a virus a/victoria/361/2011 ivr-165 (h3n2) antigen (formaldehyde inactivated) (9 ug/0.1mL) + Influenza b virus b/texas/6/2011 antigen (formaldehyde inactivated) (9 ug/0.1mL)Injection, suspensionIntradermalSanofi Pasteur Limited2012-07-022013-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza b virus b/massachusetts/2/2012 antigen (formaldehyde inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2013-06-282014-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/victoria/210/2009 x-187 (h3n2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularPhysicians Total Care, Inc.2010-09-212011-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/victoria/210/2009 x-187 (h3n2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2011-07-012012-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/massachusetts/2/2012 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2013-06-282014-06-30Us
FluzoneInfluenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza a virus a/victoria/361/2011 ivr-165 (h3n2) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza b virus b/texas/6/2011 antigen (formaldehyde inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2012-07-022013-06-30Us
Categories
Not Available
UNII
XQO8062U6R
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableMucosal Immunity1
1CompletedPreventionFlu caused by Influenza4
1CompletedPreventionFlu caused by Influenza / Gammopathy1
1RecruitingPreventionChronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1, 2CompletedPreventionEgg Allergy / Eligible for Vaccination Against Influenza1
1, 2CompletedPreventionFlu caused by Influenza2
2Active Not RecruitingPreventionFlu caused by Influenza1
2Active Not RecruitingPreventionRespiratory Tract Diseases / Respiratory Tract Infections (RTI) / RNA Virus Infections / Virus Diseases1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2CompletedPreventionBone Marrow Transplant (BMT) / Dialysis therapy / Human Immunodeficiency Virus (HIV) / Rheumatologic Disorders / Solid Organ Transplant Recipient (Liver, Kidney, Heart)1
2CompletedPreventionFlu caused by Influenza10
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection1
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxoviridae Infections1
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxovirus Infections1
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxoviruses1
2CompletedPreventionHealthy Participants1
2CompletedPreventionInfluenza Viral Infections / Malignancies1
2Not Yet RecruitingPreventionFlu caused by Influenza1
2SuspendedTreatmentPlasma Cell Myeloma1
3CompletedEducational/Counseling/TrainingFlu caused by Influenza1
3CompletedPreventionFlu caused by Influenza7
3CompletedPreventionFlu caused by Influenza / Influenza Infection1
3CompletedPreventionFlu caused by Influenza / Influenza Vaccines1
3CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxoviridae Infections2
3CompletedPreventionHerpes Zoster2
3CompletedPreventionInfluenza Disease1
3TerminatedPreventionFlu caused by Influenza1
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4Active Not RecruitingHealth Services ResearchHealthy Volunteers1
4Active Not RecruitingPreventionFlu caused by Influenza2
4CompletedBasic ScienceFlu caused by Influenza7
4CompletedBasic ScienceFlu caused by Influenza / Healthy Volunteers1
4CompletedBasic ScienceImmune Response to Influenza Vaccine / Influenza A Virus Infection / Influenza B Virus Infection1
4CompletedBasic ScienceMELAS Syndrome1
4CompletedBasic ScienceRheumatoid Arthritis1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionAdverse Drug Events / Injection Site Reactions / Pain NOS / Quality of Life / Side Effect of Drug1
4CompletedPreventionChronic Heart Failure (CHF)1
4CompletedPreventionFlu caused by Influenza20
4CompletedPreventionFlu caused by Influenza / Orthomyxoviridae Infections1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionInfluenza, Human1
4CompletedPreventionInfluenza, Human / Transplantation Infection1
4Not Yet RecruitingBasic ScienceFlu caused by Influenza1
4RecruitingNot AvailableFlu caused by Influenza1
4RecruitingBasic ScienceFlu caused by Influenza1
4RecruitingOtherSystemic Inflammatory Response1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4TerminatedBasic ScienceFlu caused by Influenza1
4TerminatedPreventionFlu caused by Influenza1
4Unknown StatusBasic ScienceFlu caused by Influenza1
4Unknown StatusPreventionHuman Response to Influenza Vaccine1
Not AvailableCompletedNot AvailableFlu caused by Influenza / H1N1 / Infection, Human Immunodeficiency Virus I1
Not AvailableCompletedNot AvailableSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedBasic ScienceFlu caused by Influenza1
Not AvailableCompletedBasic ScienceImmune Response1
Not AvailableCompletedBasic ScienceImmunity to Influenza Vaccine1
Not AvailableCompletedPreventionFlu caused by Influenza2
Not AvailableUnknown StatusPreventionCongenital Muscular Dystrophy / Duchenne's Muscular Dystrophy (DMD) / Spinal Muscular Atrophy (SMA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
Injection, suspensionIntradermal
KitIntramuscular; Topical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on June 04, 2019 07:15